Guselkumab for treating moderate to severe plaque psoriasis

2.1 Guselkumab (Tremfya, Janssen) is indicated for 'the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'.

2.2 The recommended dosage of guselkumab is 100 mg by subcutaneous injection at weeks 0 and 4, followed by a 100 mg maintenance dose every 8 weeks. Consideration should be given to stopping treatment in people whose disease has shown no response after 16 weeks of treatment.

2.3 The list price of guselkumab is £2,250 per prefilled syringe (excluding VAT; British national formulary online; accessed March 2018). The company has a commercial arrangement. This makes guselkumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.